vVARDIS Announces Investment from Apollo

Posted: April 29, 2026
Edited by Dentaltown staff

ZUG, Switzerland—vVARDIS Holding AG announced a minority investment from Apollo-managed funds to support global expansion of its Curodont product platform, a noninvasive treatment for early-stage tooth decay.

The company said the investment will accelerate commercial growth in the U.S. and Europe and expand adoption of its peptide-based formulations designed to support enamel repair without drilling.

Curodont has been used to treat approximately 3 million teeth and is present in nearly 20% of general dental practices in the U.S., according to the company.

vVARDIS said the technology offers clinicians a restorative option for early decay that avoids traditional invasive procedures.

Financial terms were not disclosed. For more information, visit vVARDIS.com or apollo.com.
Views: 72
Sponsors
Townie Perks
Townie® Poll
What do you use to take routine X-rays?